SYNAIRGEN PLC

Share Issue/Capital Change • Mar 23, 2016

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 9686S

Synairgen plc

23 March 2016

Synairgen plc

('Synairgen' or the 'Company')

Exercise of Options

Southampton, UK, 23 March 2016: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announces that it has applied for 45,941 ordinary shares of one pence each (the "Option Shares") to be admitted to trading on AIM ("Admission"). It is expected that Admission will occur and that dealings will commence in the Option Shares on 30 March 2016.

The Option Shares are being issued pursuant to the exercise of options by two employees of the Company, who are selling in aggregate 19,178 Option Shares to meet the tax and subscription liabilities arising upon exercise. The Option Shares will rank pari passu with the Company's existing ordinary shares.

The Company advises that, following Admission, the Company's issued share capital is 91,362,612 Ordinary Shares all carrying voting rights. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FSA's Disclosure and Transparency Rules.

Ends

For further enquiries, please contact:

Synairgen plc 

Richard Marsden, Chief Executive Officer

John Ward, Finance Director

Tel: + 44 (0) 23 8051 2800

finnCap

Geoff Nash, James Thompson (Corporate Finance)

Stephen Norcross, Simon Johnson (Corporate Broking)

Tel: + 44 (0) 20 7220 0500

Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott / Jessica Hodgson / Laura Thornton

synairgen@consilium-comms.com

Tel: +44 (0) 20 3709 5701

About Synairgen 

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Leveraging scientific and clinical trial facilities at the University of Southampton and Southampton General Hospital, the Company uses in vitro and ex vivo models to progress opportunities into clinical development. The BioBank of human samples is used in these models to increase confidence in the likelihood of successful drug development. Core to Synairgen's business strategy is the realisation of value via licensing transactions - validated in June 2014 by the SNG001 agreement formed with AstraZeneca. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com. 

This information is provided by RNS

The company news service from the London Stock Exchange

END

IOEAKBDDBBKBONB